Medication Overuse Headache, Chronic Migraine and Monoclonal Antibodies Anti-CGRP: A Real-World Study.

Abstract

OBJECTIVE:

Medication overuse headache (MOH) in chronic migraineurs may be a cause or consequence of the overuse of symptomatic medications for headache attacks. It is highly prevalent in tertiary centers. We compared the efficacy of 3 anti-CGRP monoclonal antibodies with traditional pharmacological agents in patients with chronic migraine (CM) and MOH.

METHODS:

A randomized, cross-sectional, prospective, and open trial with real-world comparison groups was carried out. The sample consisted of 100 consecutive patients having CM and MOH.

RESULTS:

Eighty-eight patients (65 women and 23 men) were included in the study and divided into 4 groups: those having used erenumab (19.3%), galcanezumab (29.6%), fremanezumab (25%) and conventional medications, and the control group (26.1%). Ages ranged from 18 to 78 years (mean, 44.1 ± 13.6 years). In the 6 months of follow-up, there was a significant reduction in the number of headache days in the 3 groups when compared with the control ( P < 0.0001).

CONCLUSIONS:

The small number of patients included in each group and the open design do not allow definitive conclusions, but the use of anti-CGRP monoclonal antibodies in patients with CM and MOH may result in lessening the number of headache days when compared with conventional treatment with drugs.

• Authors: Abouch Krymchantowski, Carla Jevoux, Ana Gabriela Krymchantowski, Raimundo Pereira Silva-Néto
• Journal: Clinical neuropharmacology (Clin Neuropharmacol) 2023 Sep-Oct 01 Vol. 46 Issue 5 Pg. 181-185 ISSN: 1537-162X [Electronic] United States
• PMID: 37748000 (Publication Type: Randomized Controlled Trial, Journal Article)
• Copyright: Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.

Chemical References

• Antibodies, Monoclonal

Topics

• Male
• Humans
• Female
• Adolescent
• Young Adult
• Adult
• Middle Aged
• Aged
• Prospective Studies
• Cross-Sectional Studies
• Migraine Disorders (drug therapy)
• Antibodies, Monoclonal (adverse effects)
• Headache (drug therapy)
• Headache Disorders, Secondary (drug therapy)